Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tumor metastasis is the major cause of poor prognosis and mortality in colorectal cancer (CRC). However, early diagnosis of highly metastatic CRC is currently difficult. In the present study, we screened for a novel biomarker,
GDNF family receptor alpha 1
(
GFRA1
) based on the expression and methylation data in CRC patients from The Cancer Genome Altlas (TCGA), followed by further analysis of the correlation between the
GFRA1
expression, methylation, and prognosis of patients. Our results show DNA hypomethylation-mediated upregulation of
GFRA1
in invasive CRC, and it was found to be correlated with poor prognosis of CRC patients. Furthermore,
GFRA1
methylation-modified sequences were found to have potential as methylation diagnostic markers of highly metastatic CRC. The targeted demethylation of
GFRA1
by dCas9-TET1CD and gRNA promoted CRC metastasis in vivo and in vitro. Mechanistically, demethylation of
GFRA1
induces epithelial-mesenchymal transition (EMT) by promoting AKT phosphorylation and increasing
c-Jun
expression in CRC cells. Collectively, our findings indicate that
GFRA1
hypomethylation can promote CRC invasion via inducing EMT, and thus,
GFRA1
methylation can be used as a biomarker for the early diagnosis of highly metastasis CRC.
...
PMID:Hypomethylation of GDNF family receptor alpha 1 promotes epithelial-mesenchymal transition and predicts metastasis of colorectal cancer. 3317 46